Bioengineered Extracellular Vesicles - Potential Boon for Delivering Biotherapeutics

EV-based treatments are now being evaluated for immunomodulation, tissue regeneration, recovery, and as delivery vectors for combination therapy. Moreover, EVs are critical parts of paracrine motioning in stem/progenitor cell-based treatments, can be utilized as a medication conveyance strategy or can be utilized as independent therapeutics. T cells that have been genetically modified can be utilized for everything from cancer immunotherapy to HIV treatment however getting T cell-designated drugs to patients is troublesome.

Why Extracellular Vesicles as Delivery Agents?

Extracellular vesicles (EVs) are nanoscale particles secreted by all cells that naturally encapsulated and transfer proteins and nucleic acids, making them an appealing and clinically relevant platform for constructing biomimetic delivery vehicles in the upcoming years. There are technologies for genetically engineering cells to develop multifunctional EV vehicles without the use of chemical compounds. High affinity profiling domains on the EV surface to accomplish, efficacious T cell binding, a protein tag to confer active cargo stacking into EVs, and fusogenic glycoproteins to enhance EV uptake and fusion with recipient cells are also demonstrated. These technologies operate very well together by delivering Cas9-sgRNA complexes to primary human T cells. These methodologies might lead to well enable vesicles to target to a variety of cells for efficient delivery as Cargoes.